Cargando…

The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Edward, Prousky, Jonathan, Raskin, Gannady, Gagnier, Joel, Rachlis, Beth, Montori, Victor M, Juurlink, David
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280687/
https://www.ncbi.nlm.nih.gov/pubmed/14614780
http://dx.doi.org/10.1186/1472-6904-3-4
_version_ 1782121063564443648
author Mills, Edward
Prousky, Jonathan
Raskin, Gannady
Gagnier, Joel
Rachlis, Beth
Montori, Victor M
Juurlink, David
author_facet Mills, Edward
Prousky, Jonathan
Raskin, Gannady
Gagnier, Joel
Rachlis, Beth
Montori, Victor M
Juurlink, David
author_sort Mills, Edward
collection PubMed
description BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-controlled blinded trial of a single dose of an OTC, immediate-release niacin 500 mg (n = 33), or a single dose of placebo (n = 35) on an empty stomach. The outcomes measured were self-reported incidence of flushing and other adverse effects. RESULTS: 33 volunteers on niacin (100%) and 1 volunteer on placebo (3%) flushed (relative risk 35, 95% confidence interval (CI) 6.8–194.7). Mean time to flushing on niacin was 18.2 min (95% CI: 12.7–23.6); mean duration of flushing was 75.4 min (95% CI: 62.5–88.2). Other adverse effects occurred commonly in the niacin group: chills (51.5% vs. 0%, P < .0001), generalized pruritus (75% vs. 0%, P = <.001), gastrointestinal upset (30% vs. 3%, P = .005), and cutaneous tingling (30% vs. 0%, P = <.001). Six participants did not tolerate the adverse effects of niacin and 3 required medical attention. CONCLUSION: Clinicians counseling patients about niacin should alert patients not only about flushing but also about gastrointestinal symptoms, the most severe in this study. They should not trust that patients would receive information about these side effects or their prevention (with aspirin) from the OTC packet insert.
format Text
id pubmed-280687
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-2806872003-12-02 The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] Mills, Edward Prousky, Jonathan Raskin, Gannady Gagnier, Joel Rachlis, Beth Montori, Victor M Juurlink, David BMC Clin Pharmacol Research Article BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-controlled blinded trial of a single dose of an OTC, immediate-release niacin 500 mg (n = 33), or a single dose of placebo (n = 35) on an empty stomach. The outcomes measured were self-reported incidence of flushing and other adverse effects. RESULTS: 33 volunteers on niacin (100%) and 1 volunteer on placebo (3%) flushed (relative risk 35, 95% confidence interval (CI) 6.8–194.7). Mean time to flushing on niacin was 18.2 min (95% CI: 12.7–23.6); mean duration of flushing was 75.4 min (95% CI: 62.5–88.2). Other adverse effects occurred commonly in the niacin group: chills (51.5% vs. 0%, P < .0001), generalized pruritus (75% vs. 0%, P = <.001), gastrointestinal upset (30% vs. 3%, P = .005), and cutaneous tingling (30% vs. 0%, P = <.001). Six participants did not tolerate the adverse effects of niacin and 3 required medical attention. CONCLUSION: Clinicians counseling patients about niacin should alert patients not only about flushing but also about gastrointestinal symptoms, the most severe in this study. They should not trust that patients would receive information about these side effects or their prevention (with aspirin) from the OTC packet insert. BioMed Central 2003-11-13 /pmc/articles/PMC280687/ /pubmed/14614780 http://dx.doi.org/10.1186/1472-6904-3-4 Text en Copyright © 2003 Mills et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Mills, Edward
Prousky, Jonathan
Raskin, Gannady
Gagnier, Joel
Rachlis, Beth
Montori, Victor M
Juurlink, David
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title_full The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title_fullStr The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title_full_unstemmed The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title_short The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
title_sort safety of over-the-counter niacin. a randomized placebo-controlled trial [isrctn18054903]
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280687/
https://www.ncbi.nlm.nih.gov/pubmed/14614780
http://dx.doi.org/10.1186/1472-6904-3-4
work_keys_str_mv AT millsedward thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT prouskyjonathan thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT raskingannady thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT gagnierjoel thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT rachlisbeth thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT montorivictorm thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT juurlinkdavid thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT millsedward safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT prouskyjonathan safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT raskingannady safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT gagnierjoel safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT rachlisbeth safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT montorivictorm safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903
AT juurlinkdavid safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903